Published in Q J Nucl Med on September 01, 1998
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry (2012) 2.34
From maps to mechanisms through neuroimaging of schizophrenia. Nature (2010) 2.28
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron (2010) 1.96
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des (2009) 1.51
Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology (2010) 1.47
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A (2006) 1.44
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain (2008) 1.37
Deconstructing psychosis with human brain imaging. Schizophr Bull (2007) 1.35
Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci (2009) 1.32
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl (2007) 1.31
Are we studying and treating schizophrenia correctly? Schizophr Res (2011) 1.19
Motor coordination deficits in mice lacking RGS9. Brain Res (2007) 1.11
DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.11
Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. Proc Natl Acad Sci U S A (2008) 1.10
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry (2015) 1.08
Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses (2010) 1.06
Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res (2010) 1.05
Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) (2009) 1.05
Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis. Schizophr Bull (2013) 1.04
Extracellular matrix abnormalities in schizophrenia. Neuropharmacology (2011) 1.04
Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels. J Neurosci (2012) 1.02
Schizophrenia in translation: dissecting motivation in schizophrenia and rodents. Schizophr Bull (2012) 0.99
Timing as a window on cognition in schizophrenia. Neuropharmacology (2011) 0.98
Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Hum Mol Genet (2013) 0.95
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res (2009) 0.93
Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology (2009) 0.92
Animal models of schizophrenia: a critical review. J Psychiatry Neurosci (2001) 0.91
Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophr Bull (2015) 0.91
Modeling motivational deficits in mouse models of schizophrenia: behavior analysis as a guide for neuroscience. Behav Processes (2011) 0.89
The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab (2011) 0.89
Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.86
From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des (2012) 0.86
Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry (2015) 0.82
Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia. Front Cell Neurosci (2013) 0.82
Timing of moderate level prenatal alcohol exposure influences gene expression of sensory processing behavior in rhesus monkeys. Front Integr Neurosci (2009) 0.81
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull (2015) 0.81
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull (2014) 0.81
Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter dysfunction. Transl Psychiatry (2013) 0.80
The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study. Psychopharmacology (Berl) (2011) 0.80
Towards medication-enhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol (2012) 0.80
Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) (2011) 0.80
Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci (2013) 0.79
Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Front Psychiatry (2012) 0.78
The influence of different cellular environments on PET radioligand binding: an application to D2/3-dopamine receptor imaging. Neuropharmacology (2014) 0.78
Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Med Hypotheses (2015) 0.77
Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. Synapse (2016) 0.77
New drug developments in psychosis: Challenges, opportunities and strategies. Prog Neurobiol (2016) 0.77
Homozygous Deletion of Glutathione Peroxidase 1 and Aldehyde Dehydrogenase 1a1 Genes Is Not Associated with Schizophrenia-Like Behavior in Mice. J Biochem Pharmacol Res (2013) 0.77
The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms? Psychopharmacology (Berl) (2009) 0.77
Decreasing Striatopallidal Pathway Function Enhances Motivation by Energizing the Initiation of Goal-Directed Action. J Neurosci (2016) 0.76
Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia. Cell Rep (2016) 0.76
Using human brain imaging studies as a guide toward animal models of schizophrenia. Neuroscience (2015) 0.76
Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. Psychopharmacology (Berl) (2003) 0.75
Theranostic Biomarkers for Schizophrenia. Int J Mol Sci (2017) 0.75
Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation. Biol Psychiatry (2016) 0.75
Exploring the presence of narcolepsy in patients with schizophrenia. BMC Psychiatry (2016) 0.75
A brief review on recent developments in animal models of schizophrenia. Indian J Pharmacol (2011) 0.75
Calculating occupancy when one does not have baseline: a comparison of different options. J Cereb Blood Flow Metab (2011) 0.75
Brain regions and monoaminergic neurotransmitters that are involved in mouse ambulatory activity promoted by bupropion. Toxicol Rep (2016) 0.75
Motor system dysfunction in the schizophrenia diathesis: Neural systems to neurotransmitters. Eur Psychiatry (2017) 0.75
Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Front Pharmacol (2017) 0.75